Patents Assigned to Naval Medical Research Center
-
Publication number: 20210327540Abstract: The present disclosure describes methods and systems for predicting if a subject has an increased risk of having or developing one or more clinical outcomes, including prior to the detection of symptoms thereof and/or prior to onset of any detectable symptoms thereof. The present disclosure also describes a method of generating a model for predicting one or more clinical outcomes.Type: ApplicationFiled: August 16, 2019Publication date: October 21, 2021Applicants: Henry M. Jackson Foundation for the Advancement of Military Medicine, Naval Medical Research Center, Duke University Medical Center, Emory UniversityInventors: Seth A Schobel, Vivek Khatri, Felipe Lisboa, Matthew J. Bradley, Christopher J. Dente, Timothy Buchman, Allan D. Kirk, Jonathan A. Forsberg, Todd V. Brennan, Eric A. Elster
-
Publication number: 20190060380Abstract: The subject matter of the instant invention relates to methods of enhancing harvesting of phages against a targeted host bacteria, as well as methods of identifying phages likely to have an enhanced propensity to infect and kill an infectious pathogenic bacteria in vivo, from samples comprising phages. The invention also relates to phage libraries, pharmaceutical compositions, methods of treatment, and phage-haled diagnostic methods and methods of detecting bacteria related thereto.Type: ApplicationFiled: August 24, 2018Publication date: February 28, 2019Applicants: Naval Medical Research Center, United States of America as Represented by the Secretary of the ArmyInventors: James M. Regeimbal, Stuart D. Tyner
-
Patent number: 10017547Abstract: The inventive subject matter relates to the methods for the induction of immunity and prevention of diarrhea resulting from Escherichia coli. The inventive subject matter also relates to the use Escherichia coli adhesins as immunogens and to the construction of conformationally stability and protease resistant Escherichia coli adhesin constructs useful for inducing immunity to Escherichia coli pathogenic bacteria. The methods provide for the induction of B-cell mediated immunity and for the induction of antibody capable of inhibiting the adherence and colonization of Escherichia coli, including enterotoxigenic Escherichia coli, to human cells.Type: GrantFiled: June 8, 2015Date of Patent: July 10, 2018Assignee: Naval Medical Research CenterInventor: Stephen J. Savarino
-
Publication number: 20150266932Abstract: The inventive subject matter relates to the methods for the induction of immunity and prevention of diarrhea resulting from Escherichia coli. The inventive subject matter also relates to the use Escherichia coli adhesins as immunogens and to the construction of conformationally stability and protease resistant Escherichia coli adhesin constructs useful for inducing immunity to Escherichia coli pathogenic bacteria. The methods provide for the induction of B-cell mediated immunity and for the induction of antibody capable of inhibiting the adherence and colonization of Escherichia coli, including enterotoxigenic Escherichia coli, to human cells.Type: ApplicationFiled: June 8, 2015Publication date: September 24, 2015Applicant: NAVAL MEDICAL RESEARCH CENTERInventor: Stephen J. Savarino
-
Patent number: 9079945Abstract: The inventive subject matter relates to the methods for the induction of immunity and prevention of diarrhea resulting from Escherichia coli. The inventive subject matter also relates to the use Escherichia coli adhesins as immunogens and to the construction of conformationally stability and protease resistant Escherichia coli adhesin constructs useful for inducing immunity to Escherichia coli pathogenic bacteria. The methods provide for the induction of B-cell mediated immunity and for the induction of antibody capable of inhibiting the adherence and colonization of Escherichia coli including enterotoxigenic Escherichia coli, to human cells.Type: GrantFiled: January 10, 2006Date of Patent: July 14, 2015Assignee: Naval Medical Research CenterInventor: Stephen J. Savarino
-
Publication number: 20030143652Abstract: An assay method and kit is disclosed for detecting the presence of at least one predesignated, target antibody to a mycobacterium in a sample selected from one or more patient bodily fluids. The method comprises the following steps: (a) contacting the sample of one or more patient bodily fluids with at least one mycobacterium antigen on a lateral-flow assay membrane to bind to the target antibody in the sample; (b) previously, simultaneously or subsequently to step (a), binding the at least one mycobacterium antigen with a conjugated label producing a detectable signal; and (c) detecting the signal whereby the presence of the target antibody is determined in the sample by the intensity or presence of the signal. The method can further comprise the step of evaluating immunization status of the patient from whom the sample came by comparing the signal or lack thereof with immunizations previously received by the patient and in comparison to a known standard control.Type: ApplicationFiled: January 30, 2002Publication date: July 31, 2003Applicant: The Gov. of the USA as represented by the Navy Naval Medical Research Center Office of CounselInventor: Lloyd G. Simonson
-
Publication number: 20030143636Abstract: An assay method and kit for detecting the presence of a predesignated, target IgG antibody in a sample selected from one or more patient bodily fluids. The method comprises the following steps: (a) contacting the sample of one or more patient bodily fluids with a membrane-bound recombinant protective antigen to bind to the target IgG antibody in the sample; (b) previously, simultaneously or subsequently to step (a), binding the protective antigen (PA) with a conjugated label producing a detectable signal; and (c) detecting the signal whereby the presence of the target IgG antibody is determined in the sample by the intensity of the signal. The method can further comprise the step of evaluating immunization status of the patient from whom the sample came by comparing the signal or lack thereof with immunizations previously received by the patient. In a preferred embodiment, the recombinant protective antigen (PA) specifically binds to anthrax protective antigen-specific IgG antibodies.Type: ApplicationFiled: January 30, 2002Publication date: July 31, 2003Applicant: Naval Medical Research CenterInventors: Lloyd G. Simonson, John R. Kelly